Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030002 | 0.86 | NR4A2 (0.43) | NR4A2CREBBPMAP2K1AXL | |
| SCHEMBL3033301 | 0.84 | NR4A2 (0.42) | NR4A2CREBBPMAP2K1SMN1; SMN2ABL1 | |
| SCHEMBL3027903 | 0.83 | NR4A2 (0.41) | NR4A2CREBBPMAP2K1SMN1; SMN2 | |
| SCHEMBL3033601 | 0.81 | NR4A2 (0.40) | NR4A2CREBBPMAP2K1SMN1; SMN2SERPINH1 | |
| SCHEMBL21060930 | 0.81 | LMNA (0.44) | NR4A2CREBBPMAP2K1NPSR1 | |
| SCHEMBL11201376 | 0.80 | NPSR1 (0.43) | NR4A2CREBBPMAP2K1NPSR1BRPF1 | |
| SCHEMBL21060862 | 0.79 | XDH (0.44) | NR4A2CREBBPNPSR1 | |
| SCHEMBL3017199 | 0.79 | PBRM1 (0.39) | PBRM1BRPF1 | |
| SCHEMBL3554714 | 0.79 | NR4A2 (0.42) | NR4A2CREBBPSMN1; SMN2NPSR1 | |
| SCHEMBL3035913 | 0.79 | LMNA (0.44) | NR4A2CREBBPMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | NR4A2 2805/4885CREBBP 2208/4885MAP2K1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.